-
Pfizer, Myovant begin dosing in relugolix contraceptive study
pharmatimes
April 15, 2021
Pfizer and Myovant have announced that dosing has begun in a Phase III study evaluating the contraceptive efficacy of their relugolix combination tablet.
-
Oral contraceptive pills protect against ovarian and endometrial cancer, study finds
europeanpharmaceuticalreview
December 22, 2020
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
-
Lubrizol Supports Women’s Health Worldwide
contractpharma
September 17, 2020
Awarded grant for generic contraceptive injection research to advance women’s health around the globe.
-
Mayne Pharma Submits NDA to FDA for E4/DRSP
contractpharma
April 17, 2020
Development and manufacturing partner Mithra can synthesise E4 at scale through a complex plant-based production process.
-
Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US
pharmaceutical-business-review
January 15, 2020
Bayer has entered into a licence agreement with Daré Bioscience to commercialise investigational contraceptive product called Ovaprene in the US.
-
Adolescent Oral Contraceptive Use Tied to Later Depression Risk
drugs
September 04, 2019
There is a long-term association between adolescent oral contraceptive (OC) use and depression risk in adulthood, according to a study published online in the Journal of Child Psychology and Psychiatry.
-
HIV Risk Does Not Differ With Three Contraceptive Methods
drugs
June 14, 2019
HIV Risk Does Not Differ With Three Contraceptive Methods.
-
Global contraceptive pill market to grow 6.6 percent
europeanpharmaceuticalreview
June 10, 2019
The global contraceptive pill market is expected to increase to US$8.8 billion by 2024, report finds.
-
Female Contraceptive Market set to be worth $8.7bn by 2027
biospectrumasia
February 12, 2019
China, on the other hand, will become the fourth largest contraceptive market by 2027
-
FDA Accepts Filing of New Estrogen-free Oral Contraceptive
americanpharmaceuticalreview
November 30, 2018
Exeltis has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda (4mg Drospirenone-only pill), the novel oral contraceptive developed by the company......